This phase I trial is evaluating a new intravenous drug (NZV930) alone and in combination with two other drugs (one intravenous and one oral) for the treatment of specific advanced cancers.
This trial is treating multiple types of cancer including Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer Microsatellite Stable, Ovarian Cancer and Renal Cell Carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies
Commercial Sponsor
Novartis Pharmaceuticals
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers. The main conditions or diseases eligible for inclusion in this trial include: Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer Microsatellite Stable, Ovarian Cancer and Renal Cell Carcinoma.
Not Recruiting Hospitals Read More